AxoGen, Inc. (AXGN)

[jimmybob]

AxoGen price target raised to $70 from $45 at Leerink
Leerink analyst Richard Newitter raised his price target for AxoGen to $70 from $45, while reiterating an Outperform rating on the shares. AxoGen remains one of his favorite long-term small cap growth stories capable of sustaining a 44%-plus 5-year CAGR as the analyst sees significant runway ahead for increased adoption in a large underpenetrated existing commercially targeted $2.2B "core" peripheral nerve repair market opportunity, and thinks this TAM will soon be expanding to $3B-plus as the company begins to target the use of its products in the surgical management of pain in 2019